Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment

被引:11
作者
Azimnasab-Sorkhabi, Parviz [1 ]
Soltani-asl, Maryam [1 ]
Yoshinaga, Tulio Teruo [1 ]
Dagli, Maria Lucia Zaidan [2 ]
Massoco, Cristina de Oliveira [2 ]
Junior, Jose Roberto Kfoury [1 ]
机构
[1] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Surg, Sao Paulo, Brazil
[2] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, Sao Paulo, Brazil
关键词
IDO; Kynurenine; IDO inhibitor; Immunosuppression; Cancer; Tumor microenvironment; 2,3-DIOXYGENASE IDO; T-CELLS; TRYPTOPHAN-METABOLISM; KYNURENINE PATHWAY; BREAST-CANCER; UP-REGULATION; IFN-GAMMA; EXPRESSION; INHIBITION; INDUCTION;
D O I
10.1007/s11033-023-08469-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Indoleamine-2,3 dioxygenase is a rate-limiting enzyme in the tryptophan catabolism in kynurenine pathways that has an immunosuppressive effect and supports cancer cells to evade the immune system in different cancer types. Diverse cytokines and pathways upregulate the production of indoleamine-2,3 dioxygenase enzymes in the tumor microenvironment and cause more production and activity of this enzyme. Ultimately, this situation results in anti-tumor immune suppression which is in favor of tumor growth. Several inhibitors such as 1-methyl-tryptophan have been introduced for indoleamine-2,3 dioxygenase enzyme and some of them are widely utilized in pre-clinical and clinical trials. Importantly at the molecular level, indoleamine-2,3 dioxygenase is positioned in a series of intricate signaling and molecular networks. Here, the main objective is to provide a focused view of indoleamine-2,3 dioxygenase enhancer pathways and propose further studies to cover the gap in available information on the function of indoleamine-2,3 dioxygenase enzyme in the tumor microenvironment.
引用
收藏
页码:6133 / 6145
页数:13
相关论文
共 99 条
  • [1] The balance between IL-1 and IL-1Ra in disease
    Arend, WR
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (4-5) : 323 - 340
  • [2] Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase
    Asghar, Kashif
    Farooq, Asim
    Zulfiqar, Bilal
    Loya, Asif
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (06): : 429 - 436
  • [3] Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients
    Asghar, Kashif
    Loya, Asif
    Rana, Iftikhar Ali
    Abu Bakar, Muhammad
    Farooq, Asim
    Tahseen, Muhammad
    Ishaq, Muhammad
    Masood, Iqra
    Rashid, Muhammad Usman
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2020, 11 (12): : 1018 - +
  • [4] Asghar Kashif, 2019, Asian Pac J Cancer Prev, V20, P3521, DOI 10.31557/APJCP.2019.20.11.3521
  • [5] Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan
    Asghar, Kashif
    Loya, Asif
    Rana, Iftikhar Ali
    Tahseen, Muhammad
    Ishaq, Muhammad
    Farooq, Asim
    Abu Bakar, Muhammad
    Masood, Iqra
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 475 - 481
  • [6] Identification of nucleotide polymorphism within the NeuroD1 candidate gene and its association with type 1 diabetes susceptibility in Iranian people by polymerase chain reaction-restriction fragment length polymorphism
    Asl, Maryam Soltani
    Azimnasab-Sorkhabi, Parviz
    Abolfathi, Ali-Akbar
    Aghdam, Yashar Hashemi
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2020, 33 (10) : 1293 - 1297
  • [7] IDO blockade negatively regulates the CTLA-4 signaling in breast cancer cells
    Azimnasab-Sorkhabi, Parviz
    Soltani-Asl, Maryam
    Yoshinaga, Tulio Teruo
    Massoco, Cristina de Oliveira
    Kfoury Junior, Jose Roberto
    [J]. IMMUNOLOGIC RESEARCH, 2023, 71 (05) : 679 - 686
  • [8] Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells
    Azimnasab-sorkhabi, Parviz
    Soltani-asl, Maryam
    Junior, Jose Roberto Kfoury
    [J]. HUMAN CELL, 2023, 36 (04) : 1225 - 1232
  • [9] The impact of leptin and its receptor polymorphisms on type 1 diabetes in a population of northwest Iran
    Azimnasab-Sorkhabi, Parviz
    Soltani-Asl, Maryam
    Kfoury Jr, Jose Roberto
    Algenstaedt, Petra
    Mehmetzade, Hakan Farzin
    Aghdam, Yashar Hashemi
    [J]. ANNALS OF HUMAN BIOLOGY, 2022, 49 (7-8) : 317 - 322
  • [10] Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
    Balachandran, Vinod P.
    Cavnar, Michael J.
    Zeng, Shan
    Bamboat, Zubin M.
    Ocuin, Lee M.
    Obaid, Hebroon
    Sorenson, Eric C.
    Popow, Rachel
    Ariyan, Charlotte
    Rossi, Ferdinand
    Besmer, Peter
    Guo, Tianhua
    Antonescu, Cristina R.
    Taguchi, Takahiro
    Yuan, Jianda
    Wolchok, Jedd D.
    Allison, James P.
    DeMatteo, Ronald P.
    [J]. NATURE MEDICINE, 2011, 17 (09) : 1094 - U99